SequelSEC

ABVC BIOPHARMA, INC. ABVC

Pharmaceutical Preparations · CIK 0001173313 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$509.79K
Fiscal year ended 2024-09-30
Operating income
-$4.51M
Fiscal year ended 2024-09-30
Free cash flow
Unavailable
Fiscal year ended 2024-09-30

Valuation, from the filing

Public float$37.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.45Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue125.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue1399.6%91th
Current ratio0.41x10th
Net margin-2671.8%23th
Operating margin-2416.0%24th
R&D / revenue40.9%33th
Revenue YoY growth0.0%43th

ABVC BIOPHARMA, INC. (ABVC) reported revenue of $509.79K and net income of -$4.55M for the fiscal year ended 2024-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ABVC BIOPHARMA, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ABVC BIOPHARMA, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Revenue$509.79K
Cost of revenue$139.97K
Gross profit$369.82K
Operating income-$4.51M
Net income-$4.55M
Research & development$219.48K
Weighted-average diluted sharesUnavailable
Pretax income-$5.10M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$3.48M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

ABVC BIOPHARMA, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Cash & equivalents$137.34K
Total assets$7.78M
Current assets$2.17M
Total liabilities$6.44M
Current liabilities$6.25M
Total equity incl. NCI$1.34M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.53K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

ABVC BIOPHARMA, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Operating cash flow-$1.54M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$1.68M
Net change in cash-$351.06K
Stock-based compensation$1.19M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

ABVC BIOPHARMA, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Free cash flowUnavailable
Gross margin72.5%
Operating margin-885.2%
FCF marginUnavailable
SBC / revenue232.7%
Current ratio0.35x
Revenue YoY growth-31.0%
Net margin-893.4%
R&D / revenue43.1%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABVC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-18View SEC filing
10-Q/A · Filed 2026-03-03View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ACAD ACET ACRS ACRV ACTU

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.